Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015 (2015), Article ID 293474, 9 pages
http://dx.doi.org/10.1155/2015/293474
Research Article

Nitrooleic Acid Protects against Cisplatin Nephropathy: Role of COX-2/mPGES-1/PGE2 Cascade

1Department of Nephrology, Provincial Hospital Affiliated to Shandong University, No. 324 Jingwu Road, Jinan, Shandong 250013, China
2Department of Internal Medicine, University of Utah and Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT 84112, USA

Received 19 September 2014; Revised 16 January 2015; Accepted 21 January 2015

Academic Editor: Alex Kleinjan

Copyright © 2015 Haiping Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Giaccone, “Clinical perspectives on platinum resistance,” Drugs, vol. 59, supplement 4, pp. 9–17, 37–38, 2000. View at Google Scholar · View at Scopus
  2. J. T. Hartmann and H.-P. Lipp, “Toxicity of platinum compounds,” Expert Opinion on Pharmacotherapy, vol. 4, no. 6, pp. 889–901, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. D. R. Luke, K. Vadiei, and G. Lopez-Berestein, “Role of vascular congestion in cisplatin-induced acute renal failure in the rat,” Nephrology Dialysis Transplantation, vol. 7, no. 1, pp. 1–7, 1992. View at Google Scholar · View at Scopus
  4. T. L. Cornelison and E. Reed, “Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin,” Gynecologic Oncology, vol. 50, no. 2, pp. 147–158, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. K. B. Meyer and N. E. Madias, “Cisplatin nephrotoxicity,” Mineral and Electrolyte Metabolism, vol. 20, no. 4, pp. 201–213, 1994. View at Google Scholar · View at Scopus
  6. N. Pabla and Z. Dong, “Cisplatin nephrotoxicity: mechanisms and renoprotective strategies,” Kidney International, vol. 73, no. 9, pp. 994–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Ramesh and W. Brian Reeves, “TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity,” Journal of Clinical Investigation, vol. 110, no. 6, pp. 835–842, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Cui, F. J. Schopfer, J. Zhang et al., “Nitrated fatty acids: endogenous anti-inflammatory signaling mediators,” The Journal of Biological Chemistry, vol. 281, no. 47, pp. 35686–35698, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. P. N. Cunningham, H. M. Dyanov, P. Park, J. Wang, K. A. Newell, and R. J. Quigg, “Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney,” The Journal of Immunology, vol. 168, no. 11, pp. 5817–5823, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. P. R. S. Baker, Y. Lin, F. J. Schopfer et al., “Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands,” Journal of Biological Chemistry, vol. 280, no. 51, pp. 42464–42475, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Zhang, L. Villacorta, L. Chang et al., “Nitro-oleic acid inhibits angiotensin II-induced hypertension,” Circulation Research, vol. 107, no. 4, pp. 540–548, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. P. Cole, T. K. Rudolph, N. K. H. Khoo et al., “Nitro-fatty acid inhibition of neointima formation after endoluminal vessel injury,” Circulation Research, vol. 105, no. 10, pp. 965–972, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Wang, H. Liu, Z. Jia, G. Guan, and T. Yang, “Effects of endogenous PPAR agonist nitro-oleic acid on metabolic syndrome in obese Zucker rats,” PPAR Research, vol. 2010, Article ID 601562, 7 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. F. J. Schopfer, M. P. Cole, A. L. Groeger et al., “Covalent peroxisome proliferator-activated receptor γ adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions,” The Journal of Biological Chemistry, vol. 285, no. 16, pp. 12321–12333, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Villacorta, L. Chang, S. R. Salvatore et al., “Electrophilic nitro-fatty acids inhibit vascular inflammation by disrupting LPS-dependent TLR4 signalling in lipid rafts,” Cardiovascular Research, vol. 98, no. 1, pp. 116–124, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Borniquel, E. A. Jansson, M. P. Cole, B. A. Freeman, and J. O. Lundberg, “Nitrated oleic acid up-regulates PPARγ and attenuates experimental inflammatory bowel disease,” Free Radical Biology and Medicine, vol. 48, no. 4, pp. 499–505, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Liu, Z. Jia, S. Soodvilai et al., “Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury,” The American Journal of Physiology—Renal Physiology, vol. 295, no. 4, pp. F942–F949, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Wang, H. Liu, Z. Jia et al., “Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice,” The American Journal of Physiology—Renal Physiology, vol. 298, no. 3, pp. F754–F762, 2010. View at Publisher · View at Google Scholar
  19. M. S. Rangel-Frausto, D. Pittet, M. Costigan, T. Hwang, C. S. Davis, and R. P. Wenzel, “The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study,” The Journal of the American Medical Association, vol. 273, no. 2, pp. 117–123, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Levy, A. Höke, and D. W. Zochodne, “Local expression of inducible nitric oxide synthase in an animal model of neuropathic pain,” Neuroscience Letters, vol. 260, no. 3, pp. 207–209, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Naureckiene, W. Edris, S. K. Ajit et al., “Use of a murine cell line for identification of human nitric oxide synthase inhibitors,” Journal of Pharmacological and Toxicological Methods, vol. 55, no. 3, pp. 303–313, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. F. J. Schopfer, Y. Lin, P. R. S. Baker et al., “Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor γ ligand,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2340–2345, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Rudolph, T. K. Rudolph, F. J. Schopfer et al., “Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion,” Cardiovascular Research, vol. 85, no. 1, pp. 155–166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Deng, Y. Kohda, H. Chiao et al., “Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury,” Kidney International, vol. 60, no. 6, pp. 2118–2128, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. K. N. M. Khan, C. M. Venturini, R. T. Bunch et al., “Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity,” Toxicologic Pathology, vol. 26, no. 5, pp. 612–620, 1998. View at Google Scholar · View at Scopus
  26. M. D. Breyer and R. M. Breyer, “G protein—coupled prostanoid receptors and the kidney,” Annual Review of Physiology, vol. 63, pp. 579–605, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Murakami and I. Kudo, “Prostaglandin E synthase: a novel drug target for inflammation and cancer,” Current Pharmaceutical Design, vol. 12, no. 8, pp. 943–954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. C. E. Trebino, J. L. Stock, C. P. Gibbons et al., “Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 9044–9049, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Uematsu, M. Matsumoto, K. Takeda, and S. Akira, “Lipopolysaccharide-dependent prostaglandin E(2) production is regulated by the glutathione-dependent prostaglandin E(2) synthase gene induced by the toll-like receptor 4/MyD88/NF-IL6 pathway,” Journal of Immunology, vol. 168, no. 11, pp. 5811–5816, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Boulet, M. Ouellet, K. P. Bateman et al., “Deletion of microsomal prostaglandin E2 (PGE2) synthase-1 reduces inducible and basal PGE2 production and alters the gastric prostanoid profile,” The Journal of Biological Chemistry, vol. 279, no. 22, pp. 23229–23237, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Murakami, K. Nakashima, D. Kamei et al., “Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2,” Journal of Biological Chemistry, vol. 278, no. 39, pp. 37937–37947, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. Jia, N. Wang, T. Aoyagi, H. Wang, H. Liu, and T. Yang, “Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis,” Kidney International, vol. 79, no. 1, pp. 77–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Honma, N. Takahashi, M. Shinohara et al., “Amelioration of cisplatin-induced mouse renal lesions by a cyclooxygenase (COX)-2 selective inhibitor,” European Journal of Pharmacology, vol. 715, no. 1–3, pp. 181–188, 2013. View at Publisher · View at Google Scholar · View at Scopus